rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PLRZ
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      POLYRIZON ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLAN

      TEL AVIV, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that its Board of Directors (the “Board”) has unanimously adopted a limited duration shareholder rights plan (the "Rights Plan"), effective immediately. “Unfortunately, Polyrizon, like many other development-stage biotech companies, continues to experience a signifi

      Nov 9Yahoo FinancePLRZ
      Polyrizon completes enrollment in NASARIX allergy study
      Oct 27Investing.comPLRZ
      Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
      Oct 27Yahoo FinancePLRZ
      12 Health Care Stocks Moving In Monday's After-Market Session
      Oct 26BenzingaPLRZSNTI
      Polyrizon files U.S. patent application for nasal drug delivery
      Oct 6Investing.comPLRZ
      Polyrizon enrolls first patient in U.S. allergy blocker trial
      Sep 22Investing.comPLRZ
      Polyrizon Raises $4 Million in Registered Direct Offering and Private Placement

      Tipranks Press Release.

      Sep 5The Globe and MailPLRZ
      Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement

      RAANANA, ISRAEL, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the closing of its previously announced registered direct offering and concurrent private placement. The Company issued to a single institutional investor Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also i

      Sep 4Yahoo FinancePLRZ
      Polyrizon raises $4 million in registered direct offering
      Sep 3Investing.comPLRZ
      Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement
      Sep 3Yahoo FinancePLRZ
      Polyrizon completes contracting for allergy blocker trial sites
      Sep 2Investing.comPLRZ
      Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study

      Raanana, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of NASARIX™ Allergy Blocker (PL-14). With the execution of these final agreements, Polyrizon has completed the contracting with all five U.S. clinical s

      Sep 2Yahoo FinancePLRZ

      This is the newest page. Registered accounts read further back.